



Indonesia: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility

| | | |
|---|--|---------------------|
| Project Name | Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility | |
| Project Number | 54425-001 | |
| Country | Indonesia | |
| Project Status | Approved | |
| Project Type / Modality of Assistance | Loan | |
| Source of Funding / Amount | Loan 4058-INO: Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility | |
| | Ordinary capital resources | US\$ 450.00 million |
| Strategic Agendas | Inclusive economic growth Regional integration | |
| Drivers of Change | Knowledge solutions | |
| Sector / Subsector | Health - Disease control of communicable disease | |
| Gender Equity and Mainstreaming | Some gender elements | |
| Description | The project will utilize the rapid response component (RRC) under the Asia Pacific Vaccine Access Facility (APVAX), and will provide Bio Farma with financing for vaccine procurement and logistics based on an agreed list of eligible expenditures to vaccinate priority populations against the coronavirus disease (COVID-19). The project is aligned with the following operational priorities of Strategy 2030: (i) addressing remaining poverty and reducing inequalities, (ii) accelerating progress in gender equality, and (iii) fostering regional cooperation and integration. The project is consistent with the Asian Development Bank country partnership strategy for Indonesia, 2020-2024, as it will improve the well-being of Indonesians by strengthening the health system and preventing the spread of COVID-19. | |
| Project Rationale and Linkage to Country/Regional Strategy | COVID-19 continues to spread widely in Indonesia, with more than 1.3 million people infected and about 35,000 fatalities as of early March 2021. In February 2021, the daily positivity rate (the percentage of individuals who tested positive out of the total number of individuals tested) stood at over 20% which is significantly higher than the 5% benchmark set by the World Health Organization. Surveillance systems and volunteers have been deployed to carry out contact tracing, but there remains a wide gap between the number suspected and tested. | |
| Impact | Transmission of COVID-19 reduced, public health improved, and economic productivity restored SARS-CoV-2's spread, morbidity, and mortality reduced, and confidence of citizens restored | |
| Project Outcome | | |
| Description of Outcome | Priority populations vaccinated against COVID-19 | |
| Progress Toward Outcome | | |
| Implementation Progress | | |
| Description of Project Outputs | COVID-19 vaccines procured and deployed to provinces | |
| Status of Implementation Progress (Outputs, Activities, and Issues) | | |
| Geographical Location | Nation-wide | |
| Safeguard Categories | | |
| Environment | C | |
| Involuntary Resettlement | C | |
| Indigenous Peoples | C | |
| Summary of Environmental and Social Aspects | | |
| Environmental Aspects | | |
| Involuntary Resettlement | | |
| Indigenous Peoples | | |
| Stakeholder Communication, Participation, and Consultation | | |
| During Project Design | | |
| During Project Implementation | | |
| Business Opportunities | | |

Consulting Services Not applicable. No consulting service required.

Procurement Multiple contracts for purchase of eligible vaccines through direct contracting will be financed in full or in part by up to \$445.27 million of the loan proceeds.

| | |
|----------------------------|--|
| Responsible ADB Officer | Sato, Azusa |
| Responsible ADB Department | Southeast Asia Department |
| Responsible ADB Division | Human and Social Development Division, SERD |
| Executing Agencies | PT Bio Farma (Persero) HONESTI.BASYIR@BIOFARMA.CO.ID Jl. Pasteur No.28 Bandung Jawa Barat Indonesia 40161 |

| Timetable | |
|---------------------|----------------------------|
| Concept Clearance | - |
| Fact Finding | 16 Nov 2020 to 22 Jan 2021 |
| MRM | 10 Feb 2021 |
| Approval | 31 Mar 2021 |
| Last Review Mission | - |
| Last PDS Update | 06 Apr 2021 |

Loan 4058-INO

| Financing Plan | | Loan Utilization | | | |
|----------------|--------------------------------|----------------------------|------|--------|----------------|
| | Total (Amount in US\$ million) | Date | ADB | Others | Net Percentage |
| Project Cost | 795.00 | Cumulative Contract Awards | | | |
| ADB | 450.00 | - | 0.00 | 0.00 | % |
| Counterpart | 345.00 | Cumulative Disbursements | | | |
| Cofinancing | 0.00 | - | 0.00 | 0.00 | % |

| | |
|-------------------------|---|
| Project Page | https://www.adb.org/projects/54425-001/main |
| Request for Information | http://www.adb.org/forms/request-information-form?subject=54425-001 |
| Date Generated | 08 April 2021 |

ADB provides the information contained in this project data sheet (PDS) solely as a resource for its users without any form of assurance. Whilst ADB tries to provide high quality content, the information are provided "as is" without warranty of any kind, either express or implied, including without limitation warranties of merchantability, fitness for a particular purpose, and non-infringement. ADB specifically does not make any warranties or representations as to the accuracy or completeness of any such information.